Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles.
Cell-cell communication
MND
Secreted vesicles
sporadic ALS
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
11
11
2021
received:
14
11
2020
accepted:
17
01
2022
pubmed:
24
2
2022
medline:
6
4
2022
entrez:
23
2
2022
Statut:
ppublish
Résumé
The cause of the motor neuron (MN) death that drives terminal pathology in amyotrophic lateral sclerosis (ALS) remains unknown, and it is thought that the cellular environment of the MN may play a key role in MN survival. Several lines of evidence implicate vesicles in ALS, including that extracellular vesicles may carry toxic elements from astrocytes towards MNs, and that pathological proteins have been identified in circulating extracellular vesicles of sporadic ALS patients. Because MN degeneration at the neuromuscular junction is a feature of ALS, and muscle is a vesicle-secretory tissue, we hypothesized that muscle vesicles may be involved in ALS pathology. Sporadic ALS patients were confirmed to be ALS according to El Escorial criteria and were genotyped to test for classic gene mutations associated with ALS, and physical function was assessed using the ALSFRS-R score. Muscle biopsies of either mildly affected deltoids of ALS patients (n = 27) or deltoids of aged-matched healthy subjects (n = 30) were used for extraction of muscle stem cells, to perform immunohistology, or for electron microscopy. Muscle stem cells were characterized by immunostaining, RT-qPCR, and transcriptomic analysis. Secreted muscle vesicles were characterized by proteomic analysis, Western blot, NanoSight, and electron microscopy. The effects of muscle vesicles isolated from the culture medium of ALS and healthy myotubes were tested on healthy human-derived iPSC MNs and on healthy human myotubes, with untreated cells used as controls. An accumulation of multivesicular bodies was observed in muscle biopsies of sporadic ALS patients by immunostaining and electron microscopy. Study of muscle biopsies and biopsy-derived denervation-naïve differentiated muscle stem cells (myotubes) revealed a consistent disease signature in ALS myotubes, including intracellular accumulation of exosome-like vesicles and disruption of RNA-processing. Compared with vesicles from healthy control myotubes, when administered to healthy MNs the vesicles of ALS myotubes induced shortened, less branched neurites, cell death, and disrupted localization of RNA and RNA-processing proteins. The RNA-processing protein FUS and a majority of its binding partners were present in ALS muscle vesicles, and toxicity was dependent on the expression level of FUS in recipient cells. Toxicity to recipient MNs was abolished by anti-CD63 immuno-blocking of vesicle uptake. ALS muscle vesicles are shown to be toxic to MNs, which establishes the skeletal muscle as a potential source of vesicle-mediated toxicity in ALS.
Sections du résumé
BACKGROUND
The cause of the motor neuron (MN) death that drives terminal pathology in amyotrophic lateral sclerosis (ALS) remains unknown, and it is thought that the cellular environment of the MN may play a key role in MN survival. Several lines of evidence implicate vesicles in ALS, including that extracellular vesicles may carry toxic elements from astrocytes towards MNs, and that pathological proteins have been identified in circulating extracellular vesicles of sporadic ALS patients. Because MN degeneration at the neuromuscular junction is a feature of ALS, and muscle is a vesicle-secretory tissue, we hypothesized that muscle vesicles may be involved in ALS pathology.
METHODS
Sporadic ALS patients were confirmed to be ALS according to El Escorial criteria and were genotyped to test for classic gene mutations associated with ALS, and physical function was assessed using the ALSFRS-R score. Muscle biopsies of either mildly affected deltoids of ALS patients (n = 27) or deltoids of aged-matched healthy subjects (n = 30) were used for extraction of muscle stem cells, to perform immunohistology, or for electron microscopy. Muscle stem cells were characterized by immunostaining, RT-qPCR, and transcriptomic analysis. Secreted muscle vesicles were characterized by proteomic analysis, Western blot, NanoSight, and electron microscopy. The effects of muscle vesicles isolated from the culture medium of ALS and healthy myotubes were tested on healthy human-derived iPSC MNs and on healthy human myotubes, with untreated cells used as controls.
RESULTS
An accumulation of multivesicular bodies was observed in muscle biopsies of sporadic ALS patients by immunostaining and electron microscopy. Study of muscle biopsies and biopsy-derived denervation-naïve differentiated muscle stem cells (myotubes) revealed a consistent disease signature in ALS myotubes, including intracellular accumulation of exosome-like vesicles and disruption of RNA-processing. Compared with vesicles from healthy control myotubes, when administered to healthy MNs the vesicles of ALS myotubes induced shortened, less branched neurites, cell death, and disrupted localization of RNA and RNA-processing proteins. The RNA-processing protein FUS and a majority of its binding partners were present in ALS muscle vesicles, and toxicity was dependent on the expression level of FUS in recipient cells. Toxicity to recipient MNs was abolished by anti-CD63 immuno-blocking of vesicle uptake.
CONCLUSIONS
ALS muscle vesicles are shown to be toxic to MNs, which establishes the skeletal muscle as a potential source of vesicle-mediated toxicity in ALS.
Identifiants
pubmed: 35194965
doi: 10.1002/jcsm.12945
pmc: PMC8978001
doi:
Banques de données
ClinicalTrials.gov
['NCT02360891']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1385-1402Subventions
Organisme : European Community's Health Seventh Framework Programme
ID : 259867
Organisme : Ulster University
Organisme : Northern Ireland Public Health Agency
Organisme : European Union Regional Development Fund
Organisme : ARsLA
Organisme : Target-ALS
Informations de copyright
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Acta Neuropathol. 2017 Jun;133(6):887-906
pubmed: 28243725
PLoS One. 2010 Mar 08;5(3):e9541
pubmed: 20221404
Skelet Muscle. 2016 Dec 8;6(1):43
pubmed: 27931240
Neurodegener Dis. 2012;9(1):38-52
pubmed: 21934272
J Proteomics. 2012 Dec 21;77:344-56
pubmed: 23000592
Nat Med. 2004 Aug;10(8):828-34
pubmed: 15273747
Mol Cells. 2018 Sep 30;41(9):818-829
pubmed: 30157547
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1385-1402
pubmed: 35194965
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):431-41
pubmed: 26174443
Nat Neurosci. 2019 Nov;22(11):1793-1805
pubmed: 31591561
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6439-44
pubmed: 18434538
Front Neurosci. 2018 Jul 19;12:487
pubmed: 30072868
Skelet Muscle. 2020 Jul 8;10(1):20
pubmed: 32641118
Ann Clin Transl Neurol. 2015 Feb;2(2):167-84
pubmed: 25750921
Front Mol Neurosci. 2017 Aug 31;10:276
pubmed: 28912682
Neurology. 2014 Sep 9;83(11):990-5
pubmed: 25098532
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Cell Metab. 2008 Nov;8(5):425-36
pubmed: 19046573
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
J Neurol. 2018 Oct;265(10):2454-2462
pubmed: 30054789
Int J Mol Sci. 2017 Oct 03;18(10):
pubmed: 28972545
PLoS One. 2013;8(2):e57739
pubmed: 23469062
Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19546-51
pubmed: 17164329
Sci Rep. 2018 Nov 6;8(1):16393
pubmed: 30401824
J Med Genet. 2012 Apr;49(4):258-63
pubmed: 22499346
J Extracell Vesicles. 2016 Jun 29;5:31209
pubmed: 27363484
Biochim Biophys Acta. 2016 Oct;1862(10):2004-14
pubmed: 27460707
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
J Biol Chem. 2013 May 31;288(22):15699-711
pubmed: 23592792
J Extracell Vesicles. 2017 Sep 3;6(1):1369805
pubmed: 28959386
J Pers Med. 2020 Aug 25;10(3):
pubmed: 32854276
iScience. 2020 May 22;23(5):101087
pubmed: 32371370
Front Neurosci. 2017 Jan 31;11:26
pubmed: 28197068
J Proteome Res. 2010 Feb 5;9(2):1104-20
pubmed: 20020773
Cell Rep. 2012 Oct 25;2(4):799-806
pubmed: 23022481
Cell Mol Life Sci. 2014 Mar;71(6):999-1015
pubmed: 24100629
Acta Neuropathol. 2016 Aug;132(2):175-196
pubmed: 27164932
Proc Natl Acad Sci U S A. 2012 May 29;109(22):8688-93
pubmed: 22589304
J Proteome Res. 2018 Apr 6;17(4):1712-1729
pubmed: 29513014
Cell Mol Life Sci. 2013 Jun;70(12):2159-74
pubmed: 23344255
J Cell Biol. 2009 Dec 14;187(6):761-72
pubmed: 19951898
Front Neurol. 2019 May 14;10:400
pubmed: 31139131
Antioxid Redox Signal. 2018 Apr 20;28(12):1105-1119
pubmed: 28931313
Mol Ther. 2008 Jun;16(6):1018-25
pubmed: 18414477
Nat Biotechnol. 2015 Jan;33(1):89-96
pubmed: 25383599
N Engl J Med. 2017 Oct 19;377(16):1602
pubmed: 29045202
Hum Mol Genet. 2010 Jun 1;19(11):2284-302
pubmed: 20223753
Cell Rep. 2015 Nov 10;13(6):1172-1182
pubmed: 26526994
J Neurosci Res. 2016 Nov;94(11):1333-40
pubmed: 27638615
J Cell Sci. 2015 May 1;128(9):1787-99
pubmed: 25788698
J Extracell Vesicles. 2017 Feb 28;6(1):1294368
pubmed: 28326171